Berenberg Upgrades Eli Lilly Amid Strong Performance of GLP-1 Drugs
Eli Lilly has seen significant growth due to its success with weight loss drugs, particularly Mounjaro and Zepbound. Berenberg upgraded the stock from hold to buy, raising its price target to $1,400 from $1,220, indicating a potential 23% upside. Analyst Kerry Holford highlighted confidence in Lilly's ability to maintain leadership in the obesity market and noted underappreciated pipeline investments driven by GLP-1 success. Lilly’s shares have surged over 52% in the past year as demand for GLP-1 drugs increases, with expectations that this trend will continue. The firm is also preparing new GLP-1s with easier delivery methods and anticipates significant demand following an upcoming diabetes approval of its oral drug Foundayo. Berenberg's upgrade aligns with a strong consensus on Wall Street, where 27 out of 34 analysts rate the stock as buy or stronger.
Tickers: $LLY
Topics: Earnings Potential GLP-1 Medications Pharmaceuticals Weight Loss Drugs